Skip to main content
TipRanks
Go Ultimate75% OFF

Regeneron (REGN) AI Stock Analysis

5,319 Followers
REGN

Regeneron

(NASDAQ:REGN)

Select Model
Rating:81Outperform
Price Target:$1,072.00▲(12.56% Upside)
Action:reiterated
Date:10/31/26

REGN scores well primarily due to strong financial quality (high margins, improving growth, and very low leverage) and a notably positive earnings update featuring rapid revenue/EPS growth and strong pipeline progress. The score is tempered by overbought technical conditions and only moderate valuation support given a low dividend yield, plus product-specific headwinds around legacy EYLEA declines and pricing pressure.

Positive Factors
Dupixent GrowthDupixent combines rapid sales growth with broad adoption across nine inflammatory diseases and more than 1.5 million patients. This scale supports durable commercial momentum, strengthens Regeneron’s collaboration economics with Sanofi, and provides a substantial foundation for ongoing investment.
Negative Factors
EYLEA Franchise PressureEYLEA remains an important product franchise, but falling U.S. demand and increasing biosimilar competition create a durable headwind to revenue and pricing. EYLEA HD growth may partly offset erosion, yet ongoing substitution pressure could constrain portfolio-level expansion.

Regeneron Key Performance Indicators (KPIs)

Revenue by SegmentShows how revenue is distributed across different business units, highlighting which areas are driving growth and which might need strategic adjustments.

$0.00$1.00B$2.00B$3.00B$4.00B$5.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Collaboration revenue has emerged as the primary growth driver, with a clear step‑up tied to Sanofi profit-share dynamics that will materially boost reported collaboration going forward and underpin cash generation/repurchases. Net product sales show durable momentum fueled by Dupixent scale and rapid EYLEA HD adoption, but legacy EYLEA declines and biosimilar competition create near-term headwinds and make timing of syringe approvals and manufacturing normalization key execution risks. “Other” remains small and volatile—worth watching but not a primary earnings lever.

Data provided by:The Fly

Regeneron (REGN) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%40%REGN+36.22%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$98.82B
Dividend Yield
0.39%
Average Volume (3M)
793.62K
Price to Earnings (P/E)
20.4
Beta (1Y)
0.55
Revenue Growth
18.59%
EPS Growth
8.14%
Country
US
Employees
15,410
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Regeneron Business Overview & Revenue Model

Company Description

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA,...

How the Company Makes Money

Regeneron generates revenue primarily from (1) net product sales of medicines it sells directly and (2) collaboration and other revenues from strategic partnerships (most notably with Sanofi and Bayer), plus (3) royalty and profit-sharing arrangement...

Regeneron Earnings Call Summary

Earnings Call Date:Oct 30, 2026(Q3-2026)|% Change Since:16.32%|Next Earnings Date:Jan 29, 2027
Earnings Call SentimentPositive

The call was strongly positive, supported by 36% revenue growth, 70% earnings-per-share growth, record sales for Dupixent, EYLEA HD, and Libtayo, strong cash generation, an expanded Sanofi alliance, and substantial progress across a broad clinical pipeline. The principal challenges were declining EYLEA sales and demand, biosimilar and pricing pressure, modest lynozyfic growth in its current setting, a higher expected tax rate, and no anticipated Inmazeb revenue in the fourth quarter of 2026. Highlights significantly outweighed the lowlights.

Positive Updates

Strong Third-Quarter Revenue and Earnings Growth
Total revenue increased 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share increased 70% to $20.07. The company reported its third consecutive quarter of double-digit growth in both revenue and earnings.

Negative Updates

Overall EYLEA Franchise Sales Declined
Combined U.S. EYLEA HD and EYLEA net sales were $1.1 billion in the third quarter, down 1% from the prior year. The franchise is facing increasing competition from additional 2-milligram biosimilar launches.

Company Guidance

For the fourth quarter, EYLEA HD sequential growth is expected to be approximately 10%, partially offset by ongoing pricing pressure, while EYLEA sequential demand is expected to decline in the low- to mid-teens; full year EYLEA HD net sales growth is expected to be over 50% compared with 2025, full year share repurchases are expected to total approximately $3 billion, and 2027 R&D expense is expected to increase by a mid teens percentage compared with 2026, with 100 to 200 basis points of upward pressure on the 2027 effective tax rate relative to 2026. Regeneron does not anticipate recording any revenue in the fourth quarter of 2026 for Inmazeb and expects to supply additional treatment doses to the US government beginning in late 2027 through 2031; it also expects an FDA decision for cemdisiran in November, a European Commission decision in the second half of 27, pivotal results for the knee replacement factor 11 program starting next year, a potentially registrational POTS study in the first half of next year, and registrational studies of the olatorepatide and Praluent combination next year.

Regeneron Financial Statement Overview

Summary

High-quality fundamentals: strong profitability (TTM gross margin ~84.9%, EBIT margin ~33.6%), re-accelerating revenue growth (~8.8% TTM), and an exceptionally conservative balance sheet (debt-to-equity ~0.06). Offsetting factors are normalized margins/returns versus 2021–2022 peaks and softer near-term cash conversion (OCF and FCF below net income in TTM).

Income Statement

86Very Positive

Balance Sheet

92Very Positive

Cash Flow

80Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue16.90B14.34B14.20B13.12B12.17B16.07B
Gross Profit14.49B12.24B12.23B10.87B10.47B13.35B
EBITDA6.25B5.82B5.32B4.69B5.26B9.67B
Net Income4.82B4.50B4.41B3.95B4.34B8.08B
Balance Sheet
Total Assets44.41B40.56B37.76B33.08B29.21B25.43B
Cash, Cash Equivalents and Short-Term Investments9.30B8.61B9.01B10.84B7.74B5.69B
Total Debt2.71B2.71B2.70B2.70B2.70B2.70B
Total Liabilities10.91B9.30B8.41B7.11B6.55B6.67B
Stockholders Equity33.50B31.26B29.35B25.97B22.66B18.77B
Cash Flow
Free Cash Flow3.83B4.08B3.66B3.88B4.42B6.53B
Operating Cash Flow4.85B4.98B4.42B4.59B5.01B7.08B
Investing Cash Flow-589.40M-629.10M-2.47B-3.19B-3.78B-5.38B
Financing Cash Flow-3.10B-3.72B-2.20B-1.79B-1.01B-1.01B

Regeneron Technical Analysis

Technical Analysis SentimentPositive
Last Price952.40

Price Trends

50DMA816.17Positive
100DMA774.64Positive
200DMA745.84Positive

Market Momentum

MACD42.96Negative
RSI68.37Neutral
STOCH68.49Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REGN, the sentiment is Positive. The current price of 952.40 is above the 20-day moving average (MA) of 878.88, above the 50-day MA of 816.17, and above the 200-day MA of 745.84, indicating a bullish trend. The MACD of 42.96 indicates Negative momentum. The RSI at 68.37 is Neutral, neither overbought nor oversold. The STOCH value of 68.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for REGN.

Regeneron Risk Analysis

Regeneron disclosed 47 risk factors in its most recent earnings report. Regeneron reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.There are inherent risks related to our increasing use of artificial intelligence-based solutions.Q4, 2025
2.We face risks associated with tariffs and other trade restrictions, which may have a material adverse impact on our results of operations and financial condition.Q4, 2025
3.There are inherent risks related to our increasing use of artificial intelligence-based solutions.Q3, 2025

Regeneron Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

REGN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
REGNREGN81Outperform$98.82B20.3515.07%0.39%18.59%8.14%
ARGXARGX76Outperform$60.89B45.5016.86%―70.57%30.28%
INCYINCY73Outperform$24.66B57.607.11%―24.88%-65.67%
ALNYALNY70Outperform$22.11B8.10159.72%―56.17%6459.20%
GMABGMAB63Neutral$30.47B42.8012.26%―19.61%-50.40%
BMRNBMRN56Neutral$11.09B-635.89-0.31%―19.76%-103.57%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%REGNALNYBMRNINCYARGXGMABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
REGN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
REGNRegeneron Pharmaceuticals952.40230.7631.98%
ALNYAlnylam Pharmaceuticals159.73-302.57-65.45%
BMRNBiomarin Pharmaceutical Inc.57.993.837.07%
INCYIncyte120.2716.3815.77%
ARGXArgenx950.9532.423.53%
GMABGenmab (Otc)51.5721.2570.09%

Regeneron Corporate Events

Business Operations and StrategyLegal ProceedingsPrivate Placements and Financing

Regeneron, Sanofi deepen antibody collaboration with expanded alliance

Positive
Oct 6, 2026

On October 1, 2026, Regeneron and long-time partner Sanofi expanded their antibody collaboration through a Sixth Amendment to their Antibody License and Collaboration Agreement, adding four new long-acting, Regeneron-invented antibodies targeting IL-...

Business Operations and StrategyExecutive/Board Changes

Regeneron Overhauls Executive Pay With Long-Term Performance Plan

Positive
Sep 30, 2026

On September 24, 2026, Regeneron’s board approved one-time, performance-based share unit awards for CEO Leonard Schleifer and CSO George Yancopoulos, replacing their annual long‑term equity grants through 2036 and tying compensation to a 10‑year slat...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026